Published • loading... • Updated
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
Preclinical data show LiCO-saUcp1 cut fat mass 45% in obese mice and preserved lean muscle, while semaglutide caused a 19% lean-mass loss.
- Ractigen Therapeutics announced Saturday that a late-breaking abstract on LiCO-saUcp1, its first-in-class saRNA obesity candidate, was accepted for the American Diabetes Association 86th Scientific Sessions in New Orleans.
- Utilizing proprietary Lipid-Conjugated Oligonucleotide delivery, the therapy targets the Ucp1 gene, historically considered "undruggable" by conventional pharmaceuticals. Founder and Chief Executive Officer Long-Cheng Li said the platform aims to activate the body's thermogenic switch.
- Data show LiCO-saUcp1 reduced fat mass by 45% while preserving lean muscle, contrasting sharply with semaglutide's 19% lean mass loss. When combined with semaglutide, the therapy drove a 69% fat reduction versus 47% with semaglutide alone.
- Post-Withdrawal, animals treated with LiCO-saUcp1 sustained a 46% fat mass loss for two months, preventing rapid weight regain seen with semaglutide. The therapy also reduced liver triglycerides by up to 79%, demonstrating resolution of hepatic steatosis.
- Chief Technology Officer Moorim Kang will present poster 3066-LB on Sunday, June 7, 2026, at the Ernest N. Morial Convention Center. The presentation showcases the platform technology developed by Li's team at Ractigen.
Insights by Ground AI
39 Articles
39 Articles
WJFW NewsWatch 12+38 Reposted by 38 other sources
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and preventing post-treatment weight rebound.
Coverage Details
Total News Sources39
Leaning Left4Leaning Right1Center21Last UpdatedBias Distribution81% Center
Bias Distribution
- 81% of the sources are Center
81% Center
15%
C 81%
Factuality
To view factuality data please Upgrade to Premium
